Boehringer Ingelheim (BI) and Roche have signed a pact to focus on discovering and developing orally available locked nucleic acid oligonucleotides for treating inflammatory bowel diseases.

Under the agreement, BI and Roche will collaborate on drug discovery and development, including sharing clinical development costs and responsibility for the commercialization of potential products.

Source: Boehringer Ingelheim